Trial Profile
A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab Plus Ipilimumab or Nivolumab in Combination With Oxaliplatin Plus Fluoropyrimidine Versus Oxaliplatin Plus Fluoropyrimidine in Subjects With Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 26 Feb 2024
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Capecitabine; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Registrational; Therapeutic Use
- Acronyms CheckMate649
- Sponsors Bristol-Myers Squibb
- 20 Jan 2024 Results for Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line , presented at the 2024 Gastrointestinal Cancers Symposium
- 20 Jan 2024 Results (n=208) of sub-group analysis assessing 4-year results of nivolumab plus chemotherapy vs chemotherapy in Chinese patients, presented at the 2024 Gastrointestinal Cancers Symposium.
- 12 Oct 2023 According to Ono Pharmaceutical media release, the company announced that the Japanese translation of the plain language summaries of Publication ("PLS") of study results published in Future Oncology. Ono Pharmaceutical Co., Ltd. and Bristol-Myers Squibb K.K. will provide further supports for the Japanese translation of the PLS to be published in international journal.